
A recent study investigated the impact of sex-specific differences in acute heart failure (AHF) and the implementation of novel therapies. In this international, multicenter trial, researchers analyzed 781 AHF patients, including 288 women. Women were typically older, with lower body weight and estimated glomerular filtration rate than men. The primary endpoint, a combination of all-cause mortality or AHF rehospitalization at 180 days, showed significant differences between sexes. Women in the intervention group experienced a higher risk of this combined endpoint. The study suggests that women had less successful implementation of rapid up-titration of RAAS inhibitors, potentially contributing to their higher mortality and rehospitalization rates.
Like
Save
Share